<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/89B67BA0-D9B9-44D8-A2FA-580E970CD20D"><gtr:id>89B67BA0-D9B9-44D8-A2FA-580E970CD20D</gtr:id><gtr:name>Michigan State University</gtr:name><gtr:address><gtr:line1>301 Administration Building</gtr:line1><gtr:line4>East Lansing</gtr:line4><gtr:line5>Michigan 48823-1046</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Ophthalmology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/89B67BA0-D9B9-44D8-A2FA-580E970CD20D"><gtr:id>89B67BA0-D9B9-44D8-A2FA-580E970CD20D</gtr:id><gtr:name>Michigan State University</gtr:name><gtr:address><gtr:line1>301 Administration Building</gtr:line1><gtr:line4>East Lansing</gtr:line4><gtr:line5>Michigan 48823-1046</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D92B0BD2-29CE-4C26-82A1-23AEB3502354"><gtr:id>D92B0BD2-29CE-4C26-82A1-23AEB3502354</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>W.B.</gtr:otherNames><gtr:surname>Bainbridge</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6F03635D-C7E9-423B-8EA6-1A549DE2C298"><gtr:id>6F03635D-C7E9-423B-8EA6-1A549DE2C298</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>Raihan</gtr:otherNames><gtr:surname>Ali</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ005215%2F1"><gtr:id>FE67DAC4-9AD2-4A3E-9435-64E8DDD770ED</gtr:id><gtr:title>Development of an AAV vector for treatment of inherited retinal dystrophy caused by RPE65 deficiency</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J005215/1</gtr:grantReference><gtr:abstractText>Leber congenital amaurosis (LCA) is a severe inherited retinal dystrophy with a population frequency around 1/50,000, characterised by loss of vision in childhood. Approximately 5% of LCA is caused by mutations in the RPE65 gene, which encodes a retinal pigment epithelium (RPE) specific protein essential for recycling of retinoids to the photoreceptor cells. The results of our trial, and 2 similar trials in the US, show for the first time the impact of this novel therapy on a condition that was previously untreatable. Whilst some subjects in all the trials have benefited from this new intervention, the extent of response in human subjects does not match the improvements in mice and dogs with the same genetic defect. Our data indicates that this difference reflects a greater requirement for RPE65 in humans than in rodents and dogs, and this is not fully met with the current version of the vector. The aim of this project is to improve the efficacy of gene therapy for LCA2 by optimising the RPE65 construct through a number of specific modifications. Since we have reached the maximal tolerated vector dose in these subjects, we intend to improve the efficiency of transgene expression levels by optimising the construct through a number of specific patentable modifications. By improving the efficiency of d protein production we aim to achieve a more than 100-fold reduction in the vector dose required for the optimal treatment in animal models of the disease. The RPE65 protein levels obtained from the improved vector will be tested initially in vitro. One or two constructs with a proven ability to drive higher levels of expression in vitro will be used in animal studies, first in mice and subsequently in dogs in order to test whether lower doses of the new vector can achieve equivalent rescue of retinal function and rescue of vision. 

Successful completion of this project will enable us to develop a clinical trial of an improved AAV vector for the treatment of LCA2. A more effective construct should enable us to develop a highly effective gene therapy vector that has the potential to be one of the world's first first licenced gene therapy products for clinical application. This would have considerable impact on the quality of life of the patients, with benefits ranging from improved nightvision to improved visual acuity and preservation of vision over time, depending on the condition of the retina at the time of treatment. As the best outcome is expected after treatment early in life, most commonly the end users would be pre-teen LCA2 patients, although ongoing clinical trials have shown that patients up to twenty years of age can benefit from treatment. The young age of the subjects means that a optimally successful treatment outcome could result in years of increased visual acuity and/or a wider visual field, with concomitant improvements in self-sufficiency and potentially other economic benefits. LCA is a relatively rare condition with a population frequency of approximately 1/50,000. In the UK around 5% of all forms of LCA are caused by RPE65 mutations and thus potential end-users for AAV-RPE65 gene therapy. Only patients under the age of 20 are likely to benefit from treatment; however, in this group a near-complete take-up of an established therapy is expected. 

Retinal dystrophy is a highly diverse group of disorders that can be caused by mutations in as many as 200 different genes. The core technology used in this application - subretinal injection of AAV vectors carrying a transgene - will be suitable for the development of gene therapy protocols for the majority of retinal dystrophies. Robust proof-of-concept studies have been reported for AAV-mediated gene therapy for ten forms of inherited retinal degeneration, of which we have reported five. The results obtained in this project will also facilitate the progression of these therapies to clinical application.</gtr:abstractText><gtr:technicalSummary>Leber congenital amaurosis (LCA) is a severe inherited retinal dystrophy with a population frequency around 1/50000, characterised by loss of vision in the first decade of life. Approximately 5% of LCA cases is caused by mutations in the RPE65 gene, which encodes a retinal pigment epithelium (RPE) specific protein essential for recycling of retinoids to the photoreceptor cells. Three independent clinical trials of AAV2 mediated gene therapy, including one performed by our group, have shown improvements in retinal sensitivity and vision. However, the level of improvement is lower than expected from pre-clinical experiments in rodents and dogs. Our recent data suggest this may be due to a higher need for RPE65 activity in the human eye and we therefore intend to further develop the targeting vector to drive higher transgene expression levels through a variety of patentable modifications.</gtr:technicalSummary><gtr:potentialImpactText>Leber congenital amaurosis (LCA) is the leading cause of vision loss in children, typically causing visual impairment within the first decade of life, although LCA type 2, caused by mutations in the RPE65 gene is one of the milder forms of the disease, generally leading to blindness in the second decade. Thus far, no established successful treatments exist for this disease, but on-going clinical trials - including one conducted by our group - for LCA2 have resulted in encouraging, but modest improvements in retinal sensitivity and scotopic vision. However, more substantial improvements in vision have been observed in animal studies and we have recent data to indicate that the level expression of RPE65 in the human retina is higher than in animals. This suggests that after further optimisation of the transfer vector, a more substantial rescue of vision should be feasible. A more effective construct should enable us to develop a highly effective gene therapy vector that has the potential to be one of the world's first first licenced gene therapy products for clinical application. This would have considerable impact on the quality of life of the patients, with benefits ranging from improved nightvision to improved visual acuity and preservation of vision over time, depending on the condition of the retina at the time of treatment. As the best outcome is expected after treatment early in life, most commonly the end users would be pre-teen LCA2 patients, although ongoing clinical trials have shown that patients up to twenty years of age can benefit from treatment. The young age of the subjects means that a optimally successful treatment outcome could result in years of increased visual acuity and/or a wider visual field, with concomitant improvements in self-sufficiency and potentially other economic benefits. LCA is a relatively rare condition with a population frequency of approximately 1/50,000. In the UK around 5% of all forms of LCA are caused by RPE65 mutations and thus potential end-users for AAV-RPE65 gene therapy. Only patients under the age of 20 are likely to benefit from treatment; however, in this group a near-complete take-up of an established therapy is expected. 

Retinal dystrophy is a highly diverse group of disorders that can be caused by mutations in as many as 200 different genes. The core technology used in this application - subretinal injection of AAV vectors carrying a transgene - will be suitable for the development of gene therapy protocols for the majority of retinal dystrophies. Robust proof-of-concept studies have been reported for AAV-mediated gene therapy for ten forms of inherited retinal degeneration, of which we have reported five. The results obtained in this project will also facilitate the progression of these therapies to clinical application.</gtr:potentialImpactText><gtr:fund><gtr:end>2013-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>304455</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Michigan State University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>College of Veterinary Medicine</gtr:department><gtr:description>University of Michigan</gtr:description><gtr:id>7D1C2FFB-479E-48E4-901E-0532087D4DF0</gtr:id><gtr:impact>publications and data for clinical trials regulatory submissions</gtr:impact><gtr:partnerContribution>The partners test our gene therapy vectors in their dog models of inherited retinal disease</gtr:partnerContribution><gtr:piContribution>We provide gene therapy vectors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>FBI AGM</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>985A5251-0F4B-472A-8907-F56F7CE4CDBC</gtr:id><gtr:impact>AGM Fighting Blindness, Ireland

research circulated to patients</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AMD Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AF4911FD-AA31-4CEE-B3AC-4D08D6507677</gtr:id><gtr:impact>This free one-day event organised by Prof. Ali's team provided an opportunity for people with Age-Related Macular Degeneration (AMD) to hear first-hand about the progress being made in world-leading research into gene and stem cell therapies as well as devices for AMD. Over 60 clinicians (including consultants), researchers, students and members of charitable organisations who fund research attended the day to assist and learn from the event, with many of Prof. Ali's group also giving talks or presenting posters. 

189 people attended and the audience largely consisted of patients and their relatives/friends/carers who were mostly from the UK, particularly the Greater London area, but also from Brussels, Antwerp, Barcelona and Texas. 

The day began with a series of short talks, which generated numerous questions and discussions. The afternoon session was an exhibition of posters, stalls and information from relevant charities and demonstrations by our event partner, the Macular Society. This offered the opportunity for guests to speak to researchers and clinicians one on one and to provide valuable feedback, through interactive posters, on our event/engagement activities and research focus. The charities provided advice on the the support available and to demonstrate new visual aids available to them.

Pre and post event questionnaires were completed by the attendees to help us ensure that their needs were met and how to make improvements for future events. There was a 70% return on questionnaires and the key findings were:

- 97% of the attendees felt the event met or exceed their expectations
- The majority of attendees felt the event had increased their knowledge about AMD
- The results of the 'Where do you think their needs to be more focus and support for people with AMD?' poster demo</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/ioo/genetics/gene-and-cell-therapy/amd-day-2014</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Departmental website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>88C25880-7DA2-4621-9880-7B92CB871B6C</gtr:id><gtr:impact>Regular updates to departmental website giving an over view of work being conducted.

Attracted research funds from a donor</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BRPS AGM</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EC459E4D-E7EB-4BBC-8A1E-AF90A5688894</gtr:id><gtr:impact>British Retinitis Pigmentosa Society AGM

circulated research findings to patients</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Retina Patient Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BFEBBE84-A00F-456E-B71F-DEF05B1DFDCB</gtr:id><gtr:impact>We organised a day for patients with retinal disorders to hear about our my groups gene and cell therapy research. 
350 patients and their families attended. We presented 50 posters and gave 8 short talks.

Increased interest in our website updates and increased donations.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Public Engagement</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>100847/Z/13/Z</gtr:fundingRef><gtr:id>050FD6CA-6320-45A2-8A86-29046EFBFE25</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>794946</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BRC Theme</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institutes of Health Research</gtr:fundingOrg><gtr:fundingRef>BRC3_002</gtr:fundingRef><gtr:id>51365996-4959-4649-ADF7-705785552D6F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2152639</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant (CNGB3)</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K025589/1</gtr:fundingRef><gtr:id>CE7D86BB-1112-4BAE-B40C-8FDAD54DB54C</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>737000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Equipment grant (retinal imaging)</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>099173/Z/12/Z</gtr:fundingRef><gtr:id>362C3BBD-D080-411C-B1DC-473BC3B6FF14</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Optimised AAV vector for treatment of LCA2</gtr:description><gtr:id>6A97AD96-CF6C-40EF-BFA5-1AFED9CB6581</gtr:id><gtr:impact>Paper published in Gene Therapy (Georgiadis et al 2016)</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>PCT1502137.1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Optimised gene therapy vector for RPE65 deficiency</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Athena Vision Ltd</gtr:companyName><gtr:description>Ocular gene therapy company</gtr:description><gtr:id>C9E799F1-0DB1-4C75-80ED-EA19A2F4783C</gtr:id><gtr:impact>Has raised substantial funding and will develop a programme of clinical trials with 2 new multi-centre US/UK trials of ocular gene therapy over the next 3 years. Has secured GMP facility for manufacturing for viral vectors.</gtr:impact><gtr:url>http://www.athena-vision.com</gtr:url><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F02B3E9A-26BD-456B-AE76-57CC3D2C5E9D"><gtr:id>F02B3E9A-26BD-456B-AE76-57CC3D2C5E9D</gtr:id><gtr:title>RPE65 gene therapy slows cone loss in Rpe65-deficient dogs.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/536fd39b0d7b580aba4a669ac0e843f5"><gtr:id>536fd39b0d7b580aba4a669ac0e843f5</gtr:id><gtr:otherNames>Mowat FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EADB932E-E520-4125-91AB-2CD35B201172"><gtr:id>EADB932E-E520-4125-91AB-2CD35B201172</gtr:id><gtr:title>Gene therapy in the second eye of RPE65-deficient dogs improves retinal function.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/85c51ed0cb13d9f695263c140051e258"><gtr:id>85c51ed0cb13d9f695263c140051e258</gtr:id><gtr:otherNames>Annear MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AFDF3973-C928-430C-866E-11C1B422D587"><gtr:id>AFDF3973-C928-430C-866E-11C1B422D587</gtr:id><gtr:title>Gene therapy restores vision in rd1 mice after removal of a confounding mutation in Gpr179.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0799f08f5ca57bd680ad37903ac8fc74"><gtr:id>0799f08f5ca57bd680ad37903ac8fc74</gtr:id><gtr:otherNames>Nishiguchi KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3D4A526A-12CC-4CD3-8B9F-8504CB97DB88"><gtr:id>3D4A526A-12CC-4CD3-8B9F-8504CB97DB88</gtr:id><gtr:title>Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9a491efd46cf469543e73fcb052fbbfd"><gtr:id>9a491efd46cf469543e73fcb052fbbfd</gtr:id><gtr:otherNames>Thompson DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/02542F63-88A3-4473-AB44-2E9DE0F1E656"><gtr:id>02542F63-88A3-4473-AB44-2E9DE0F1E656</gtr:id><gtr:title>Successful gene therapy in older Rpe65-deficient dogs following subretinal injection of an adeno-associated vector expressing RPE65.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/85c51ed0cb13d9f695263c140051e258"><gtr:id>85c51ed0cb13d9f695263c140051e258</gtr:id><gtr:otherNames>Annear MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/390F378E-1C39-4F46-9503-C3F4E1AA2090"><gtr:id>390F378E-1C39-4F46-9503-C3F4E1AA2090</gtr:id><gtr:title>Impact of BREXIT on UK Gene and Cell Therapy: The Need for Continued Pan-European Collaboration.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3922d5f9e6997d63b7abe51dcf409b86"><gtr:id>3922d5f9e6997d63b7abe51dcf409b86</gtr:id><gtr:otherNames>Baker AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F15F000-F8AA-4A83-9FEB-C9857D929F40"><gtr:id>2F15F000-F8AA-4A83-9FEB-C9857D929F40</gtr:id><gtr:title>Spectral sensitivity measurements reveal partial success in restoring missing rod function with gene therapy.</gtr:title><gtr:parentPublicationTitle>Journal of vision</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eac5db3178ad0308d8f39daf63bce9b0"><gtr:id>eac5db3178ad0308d8f39daf63bce9b0</gtr:id><gtr:otherNames>Ripamonti C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1534-7362</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F997BBD-3285-4EB0-A13D-F3D113694DB5"><gtr:id>2F997BBD-3285-4EB0-A13D-F3D113694DB5</gtr:id><gtr:title>Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2692eb3791498ab9cd158794f5130561"><gtr:id>2692eb3791498ab9cd158794f5130561</gtr:id><gtr:otherNames>Georgiadis A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/849CD939-7CC6-4C85-95F3-1E8D03F5CFAE"><gtr:id>849CD939-7CC6-4C85-95F3-1E8D03F5CFAE</gtr:id><gtr:title>Gene therapy for retinal dystrophies: twenty years in the making.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/875e2aeef9e3e72d4095bb70bf301cf0"><gtr:id>875e2aeef9e3e72d4095bb70bf301cf0</gtr:id><gtr:otherNames>Ali RR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F8B7306-D8F9-4786-A956-11A35CC2AEA5"><gtr:id>0F8B7306-D8F9-4786-A956-11A35CC2AEA5</gtr:id><gtr:title>Long-term effect of gene therapy on Leber's congenital amaurosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/302e5d4c10875c411f1549c6c495119d"><gtr:id>302e5d4c10875c411f1549c6c495119d</gtr:id><gtr:otherNames>Bainbridge JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D3972618-59CA-4A02-B13D-C9B779F1ADBC"><gtr:id>D3972618-59CA-4A02-B13D-C9B779F1ADBC</gtr:id><gtr:title>Gene augmentation trials using the Rpe65-deficient dog: contributions towards development and refinement of human clinical trials.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2f9de615092a52400864a8191528adf1"><gtr:id>2f9de615092a52400864a8191528adf1</gtr:id><gtr:otherNames>Petersen-Jones SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1FC8639E-8089-4029-A100-507F9656193E"><gtr:id>1FC8639E-8089-4029-A100-507F9656193E</gtr:id><gtr:title>Rescue of mutant rhodopsin traffic by metformin-induced AMPK activation accelerates photoreceptor degeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44a9ec63ff17072bf202da06d7102498"><gtr:id>44a9ec63ff17072bf202da06d7102498</gtr:id><gtr:otherNames>Athanasiou D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6F71B26-B387-405E-A5A9-DE5B111E96B3"><gtr:id>E6F71B26-B387-405E-A5A9-DE5B111E96B3</gtr:id><gtr:title>Nature of the visual loss in observers with Leber's congenital amaurosis caused by specific mutations in RPE65.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eac5db3178ad0308d8f39daf63bce9b0"><gtr:id>eac5db3178ad0308d8f39daf63bce9b0</gtr:id><gtr:otherNames>Ripamonti C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J005215/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>